Autolus Therapeutics (AUTL) news
Recent news
Autolus Therapeutics - Registers up to 3,500,000 American depositary shares representing 3,500,000 ordinary shares - SEC filing
Autolus Therapeutics Inc. has filed with the U.S. Securities and Exchange Commission (SEC) to register up to 3,500,000 American depositary shares (ADSs), with each ADS representing one ordinary share of the company[1]. The filing, made under Form F-1, indicates the company’s intention to offer and…
AInvest Wire · Sep 14, 2026Autolus Therapeutics gets FDA RMAT designation for Obe-cel
AInvest Wire · Sep 9, 2026Autolus Therapeutics - Phase 1 Carlyle trial data in SLE to be presented at ACR meeting in Q4 2026
AInvest Wire · Sep 9, 2026Autolus Therapeutics - Lumina phase 2 study of Obe-cel in LN enrolling, data expected in 2028
AInvest Wire · Sep 9, 2026Autolus Therapeutics - Q2 2026 net product revenue $45.70 mln vs $20.90 mln in Q2 2025
Autolus Therapeutics (Nasdaq: AUTL) reported preliminary second-quarter 2026 net product revenue of $45.7 million for AUCATZYL (obecabtagene autoleucel; obe-cel), a significant increase from $20.9 million in the same period in 2025. The year-over-year growth reflects a 119% increase in revenue and…
AInvest Wire · Aug 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.